Evidence map›Paper›PMID 40473811›Full record

ArticleScientific reports2025

Design and synthesis of 3,4-seco-lupane triterpene-tryptamine derivatives and revealing their anti-bladder cancer mechanisms by combining TCGA and transcriptomic approaches.

Qinglong Chi, Hongbo Teng, Yaru Zhao, Xv Wang, Jiexin Zhang, Huiyue Shen, Xuan He, Yan Zhao, Chunxi Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qinglong ChiDepartment of Urology, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.
Hongbo TengCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.
Yaru ZhaoCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.
Xv WangCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.
Jiexin ZhangCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.
Huiyue ShenCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.
Xuan HeCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.
Yan ZhaoCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.
Chunxi WangDepartment of Urology, The First Hospital of Jilin University, Changchun, 130021, Jilin, China. chunxi@jlu.edu.cn.

Funding

the Synergistic treatment of prostate cancer with a bilayer bionic nanocarrier system grant (JSWSRCZX2020-003)
6 · The paper itself

Abstract

Bladder cancer is the most common malignant tumor of the urinary tract. In this study, 90 lupane triterpene derivatives, previously synthesized in the laboratory, were systematically evaluated for their potential effects against bladder cancer by cytotoxicity screening against five urinary tumor cell lines. Bioinformatics and molecular dynamics methods were used to investigate the mechanism of action of compound 27 in depth. Most of the derivatives effectively inhibited tumor cell growth, and structure-activity relationship analysis revealed that introducing an indole moiety significantly enhanced the biological activity. The peak activity was reached when the dibromoalkyl chain length was C = 5 (IC

Indexed as

Antineoplastic AgentsTranscriptomeTriterpenesUrinary Bladder NeoplasmsApoptosisCell Line, TumorCell ProliferationDrug DesignDual-Specificity PhosphatasesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMolecular Docking SimulationStructure-Activity RelationshipAntineoplastic AgentsDual-Specificity PhosphatasesDUSP5 protein, humanTriterpenesBladder cancerseco-lupane triterpene derivativesTCGATranscriptomics

Identifiers

PMID40473811
PMCPMC12141488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.